Prognostic value of the soluble interleukin-2 receptor level after patients with follicular lymphoma achieve a response to R-CHOP

Hematology. 2017 Oct;22(9):521-526. doi: 10.1080/10245332.2017.1312204. Epub 2017 Apr 17.

Abstract

Objectives: Follicular lymphoma (FL) is a clinically and biologically heterogeneous disease. Therefore, it is important to identify factors that can predict its clinical outcome.

Methods: We retrospectively evaluated the usefulness of soluble interleukin-2 receptor (sIL-2R) levels after R-CHOP (posttreatment sIL-2R) in 72 patients with newly diagnosed FL who had either a complete response (CR) or partial response. With the use of a recursive partitioning analysis, we determined the cut-off values of post- and pretreatment sIL-2R levels that were associated with disease progression, which corresponded to 486.5 and 5405 U/mL, respectively.

Results: The high posttreatment sIL-2R group showed a significantly inferior progression-free survival (PFS) compared to the low posttreatment sIL-2R group in all patients (3-year PFS 52.6% vs. 77.4%, P = 0.003), and in patients with CR (3-year PFS 57.1% vs. 82.1%, P = 0.034). Although a multivariate analysis showed that pretreatment sIL-2R, but not posttreatment sIL-2R, was an independently significant predictive factor for disease progression, among patients with low pretreatment sIL-2R levels, those with high posttreatment sIL-2R levels tended to have inferior PFS. There was a significant trend in PFS among the high pretreatment sIL-2R group, the low pre- and high posttreatment sIL-2R group, and the low pre- and low posttreatment sIL-2R group (P < 0.001).

Conclusion: Among patients with a low pretreatment sIL-2R level who exhibited a positive response to R-CHOP, the posttreatment sIL-2R level may help to identify those with a poor prognosis.

Keywords: Follicular lymphoma; R-CHOP; posttreatment; pretreatment; prognostic factor; recursive partitioning analysis; rpart; soluble interleukin-2 receptor.

MeSH terms

  • Adult
  • Aged
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Combined Chemotherapy Protocols
  • Biomarkers
  • Cyclophosphamide
  • Doxorubicin
  • Female
  • Humans
  • Kaplan-Meier Estimate
  • Lymphoma, Follicular / blood*
  • Lymphoma, Follicular / diagnosis
  • Lymphoma, Follicular / drug therapy
  • Lymphoma, Follicular / mortality*
  • Male
  • Middle Aged
  • Neoplasm Grading
  • Neoplasm Staging
  • Prednisone
  • Prognosis
  • Proportional Hazards Models
  • Receptors, Interleukin-2 / blood*
  • Retrospective Studies
  • Rituximab
  • Treatment Outcome
  • Vincristine

Substances

  • Antibodies, Monoclonal, Murine-Derived
  • Biomarkers
  • R-CHOP protocol
  • Receptors, Interleukin-2
  • Rituximab
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Prednisone